James Andrea's most recent trade in Insight Molecular Diagnostics Inc. was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on Oct. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 50,000 | 201,231 (0%) | 0% | 0 | Common Stock | |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Oct 2025 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 50,000 | 201,231 (0%) | 0% | 0 | Common Stock | |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.01 per share. | 31 Oct 2025 | 12,175 | 189,056 (0%) | 0% | 6.0 | 73,172 | Common Stock |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2025 | 235,000 | 235,000 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 113,207 | 113,207 | - | - | Restricted Stock Units | |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.05 per share. | 07 Feb 2025 | 97,561 | 151,231 (0%) | 0% | 2.0 | 200,000 | Common Stock, no par value |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.29 per share. | 05 Dec 2024 | 20,000 | 53,670 (0%) | 0% | 2.3 | 45,800 | Common Stock, no par value |
| Insight Molecular Diagnostics Inc | James Andrea | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2024 | 200,000 | 200,000 | - | - | Options to Purchase Common Stock | |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2024 | 100,000 | 100,000 | - | - | Restricted Stock Units | |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.97 per share. | 02 Oct 2024 | 33,670 | 33,670 (0%) | 0% | 3.0 | 100,000 | Common Stock, no par value |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 200,000 | 200,000 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnostics Inc | Andrea James | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 100,000 | 300,000 | - | - | Restricted Stock Units |